Largest biotech companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Amgen leads the 21 biotech companies ranked by revenue, at NOK 356B, ahead of Gilead Sciences (NOK 285.2B) and Biogen (NOK 95.8B). Figures as of 18 Nov 2026, 18:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 21
- First
- AmgenNOK 356B
- Median
- NOK 11.8B
- Combined market value
- NOK 8.14T
- Countries
- 5
- Not ranked
- 3no revenue on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | NOK 356B | NOK 2.34T | NOK 4,323.91 | 2.52% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | NOK 285.2B | NOK 2.03T | NOK 1,637.10 | 0.73% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | NOK 95.8B | NOK 361B | NOK 2,442.04 | 0.53% up | 49% up | ||
| 4 | argenxARGX · Health Care | NOK 40.2B | NOK 576.8B | NOK 9,172.39 | 0.06% down | 4% up | ||
| 5 | BioNTechBNTX · Health Care | NOK 30.8B | NOK 201.5B | NOK 812.59 | 1.14% down | 16% down | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | NOK 27.7B | NOK 160.8B | NOK 1,588.28 | 1.18% down | 20% up | ||
| 7 | ExelixisEXEL · Health Care | NOK 22.5B | NOK 163.1B | NOK 668.55 | 0.76% up | 63% up | ||
| 8 | QiagenQGEN · Health Care | NOK 20.2B | NOK 99.4B | NOK 481.41 | 0.10% down | 12% up | ||
| 9 | ModernaMRNA · Health Care | NOK 18.8B | NOK 782.8B | NOK 1,934.71 | 3.42% down | 755% up | ||
| 10 | Halozyme TherapeuticsHALO · Health Care | NOK 13.5B | NOK 106.4B | NOK 933.28 | 0.40% up | 37% up | ||
| 11 | Bio-TechneTECH · Health Care | NOK 11.8B | NOK 110.8B | NOK 705.17 | 0.23% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | NOK 7.2B | NOK 107.4B | NOK 1,679.62 | 6.92% up | 5% up | ||
| 13 | Krystal BiotechKRYS · Health Care | NOK 3.8B | NOK 90.5B | NOK 3,054.32 | 5.62% up | 46% up | ||
| 14 | Twist BioscienceTWST · Health Care | NOK 3.6B | NOK 78.2B | NOK 1,146.97 | 5.72% up | 340% up | ||
| 15 | Adaptive BiotechnologiesADPT · Health Care | NOK 2.7B | NOK 45.2B | NOK 278.92 | 1.07% up | 88% up | ||
| 16 | ImmunityBioIBRX · Health Care | NOK 1.1B | NOK 69.2B | NOK 65.04 | 7.27% up | 193% up | ||
| 17 | Kymera TherapeuticsKYMR · Health Care | NOK 379.8M | NOK 101B | NOK 1,182.71 | 0.48% up | 87% up | ||
| 18 | CG OncologyCGON · Health Care | NOK 39.1M | NOK 69.4B | NOK 777.14 | 1.63% up | 85% up | ||
| 19 | CRISPR TherapeuticsCRSP · Health Care | NOK 34M | NOK 39B | NOK 401.55 | 3.25% up | 21% down | ||
| 20 | Revolution MedicinesRVMD · Health Care | NOK 0 | NOK 336.4B | NOK 1,555.35 | 1.30% down | 131% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | NOK 0 | NOK 56.2B | NOK 460.78 | 5.52% up | 14% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6864 NOK). 3 companies have no revenue on file and are not ranked here.
Questions and answers
Which biotech companies rank first by revenue?
Amgen (NOK 356B), Gilead Sciences (NOK 285.2B) and Biogen (NOK 95.8B) are the top three of the 21 biotech companies ranked by revenue as of 18 Nov 2026, 18:41 UTC.
How many biotech companies are in this ranking?
21 are ranked by revenue. 3 more have no revenue on file and are left out rather than ranked at zero.
What are these biotech companies worth together?
The 21 biotech companies ranked by revenue have a combined market value of NOK 8.14T as of 18 Nov 2026, 18:41 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech companies by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.